Senti Biosciences Inc SNTI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNTI is a good fit for your portfolio.
News
-
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
-
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
-
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
-
Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition Companies
-
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
Trading Information
- Previous Close Price
- $0.36
- Day Range
- $0.35–0.38
- 52-Week Range
- $0.27–1.10
- Bid/Ask
- $0.35 / $0.39
- Market Cap
- $17.20 Mil
- Volume/Avg
- 18 / 116,245
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.87
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 48
- Website
- https://www.sentibio.com
Valuation
Metric
|
SNTI
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.31 |
Price/Sales | 17.87 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
SNTI
|
---|---|
Quick Ratio | 4.33 |
Current Ratio | 5.79 |
Interest Coverage | — |
Quick Ratio
SNTI
Profitability
Metric
|
SNTI
|
---|---|
Return on Assets (Normalized) | −40.34% |
Return on Equity (Normalized) | −63.91% |
Return on Invested Capital (Normalized) | −45.77% |
Return on Assets
SNTI
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hrrcvjpc | Xtzm | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kxcffngc | Fxmmvz | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Myggbsmy | Tntwxmb | $107.6 Bil | |
MRNA
| Moderna Inc | Tvyktnx | Zvstg | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Xldvbsfbx | Bck | $22.2 Bil | |
ARGX
| argenx SE ADR | Fnbvpxr | Nyb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mvrxxnrwf | Tsdct | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yxyjpct | Llmkpm | $15.1 Bil | |
INCY
| Incyte Corp | Fmmmqjww | Krqnt | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ctbvmkkdkl | Yvwxmc | $12.7 Bil |